Total Payments
$943,500
2023 Payments
$133,750
Companies
3
Transactions
19
Medicare Patients
37
Medicare Billing
$4,657
Payment Breakdown by Category
Research$786,750 (83.4%)
Consulting$156,750 (16.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $786,750 | 11 | 83.4% |
| Consulting Fee | $156,750 | 8 | 16.6% |
Payments by Type
Research
$786,750
11 transactions
General
$156,750
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ModernaTX, Inc. | $895,250 | 16 | $0 (2023) |
| Moderna TX, Inc. | $25,250 | 1 | $0 (2021) |
| T2 Biosystems, Inc. | $23,000 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $133,750 | 6 | ModernaTX, Inc. ($133,750) |
| 2022 | $724,750 | 9 | ModernaTX, Inc. ($724,750) |
| 2021 | $62,000 | 2 | ModernaTX, Inc. ($36,750) |
| 2018 | $12,000 | 1 | T2 Biosystems, Inc. ($12,000) |
| 2017 | $11,000 | 1 | T2 Biosystems, Inc. ($11,000) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/15/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Consulting Fee | Cash or cash equivalent | $6,250.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 04/20/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 03/29/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Consulting Fee | Cash or cash equivalent | $8,500.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 03/16/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Consulting Fee | Cash or cash equivalent | $12,250.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/09/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Consulting Fee | Cash or cash equivalent | $44,500.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 01/12/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Consulting Fee | Cash or cash equivalent | $57,000.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/08/2022 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $11,750.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 11/17/2022 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $90,250.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 09/20/2022 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $50,000.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 09/01/2022 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $43,000.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 07/08/2022 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $190,000.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 06/02/2022 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $105,250.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 06/02/2022 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $40,750.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 04/08/2022 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $123,500.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 03/11/2022 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $70,250.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 12/23/2021 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $36,750.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 06/24/2021 | Moderna TX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $25,250.00 | Research |
| Study: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older • Category: Infections and Infectious Diseases | ||||||
| 10/04/2018 | T2 Biosystems, Inc. | — | Consulting Fee | Cash or cash equivalent | $12,000.00 | General |
| 01/01/2017 | T2 Biosystems, Inc. | Molecular Diagnostic Instrument (Device) | Consulting Fee | Cash or cash equivalent | $11,000.00 | General |
| Category: T2Dx | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | ModernaTX, Inc. | $761,500 | 10 |
| A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | Moderna TX, Inc. | $25,250 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 3 | 37 | 46 | $22,140 | $4,657 |
Total Patients
37
Total Services
46
Medicare Billing
$4,657
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $9,900 | $2,080 | 21.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 17 | $7,225 | $1,520 | 21.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 17 | $5,015 | $1,057 | 21.1% |
About Dr. Eric Rosenberg, MD
Dr. Eric Rosenberg, MD is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1801877691.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Rosenberg, MD has received a total of $943,500 in payments from pharmaceutical and medical device companies, with $133,750 received in 2023. These payments were reported across 19 transactions from 3 companies. The most common payment nature is "" ($786,750).
As a Medicare-enrolled provider, Rosenberg has provided services to 37 Medicare beneficiaries, totaling 46 services with total Medicare billing of $4,657. Data is available for 1 year (2021–2021), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Infectious Disease
- Location Boston, MA
- Active Since 11/08/2005
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1801877691
Products in Payments
- Moderna Covid-19 Vaccine (Biological) $920,500
- Molecular Diagnostic Instrument (Device) $11,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
Internal Medicine $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Internal Medicine $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Internal Medicine $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Internal Medicine $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M